InsiderTrades.com logo
Behzad Aghazadeh net worth and biography
  • LinkedIn
  • Phone
  • Website

Behzad Aghazadeh Biography and Net Worth

Director of Scribe Therapeutics

Behzad has 25 years of experience in the biopharmaceutical industry, with 15 years of experience as an institutional investor. He began his career in healthcare as a research scientist, later joining Booz Allen as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries. Behzad served as the Chairman of Immunomedics, a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of cancers and other diseases with high unmet medical need, until the company's $21B acquisition by Gilead in 2020. Behzad received his Master's degree in Physics from the Ludwig-Maximilians-University (Munich, Germany) and a PhD from Cornell University in Biochemistry & Biophysics.

What is Behzad Aghazadeh's net worth?

The estimated net worth of Behzad Aghazadeh is at least $99.28 million as of July 28th, 2026. Dr. Aghazadeh owns 3,088,888 shares of Scribe Therapeutics stock worth more than $99,276,860 as of September 17th. This net worth estimate does not reflect any other investments that Dr. Aghazadeh may own. Learn More about Behzad Aghazadeh's net worth.

How do I contact Behzad Aghazadeh?

The corporate mailing address for Dr. Aghazadeh and other Scribe Therapeutics executives is 1150 Marina Village Pkwy, Alameda, CA, 94501. Scribe Therapeutics can also be reached via phone at (510) 454-0213. Learn More on Behzad Aghazadeh's contact information.

Has Behzad Aghazadeh been buying or selling shares of Scribe Therapeutics?

Over the course of the past ninety days, Behzad Aghazadeh has bought $36,251,761.20 of Scribe Therapeutics stock. Most recently, on Tuesday, July 28th, Behzad Aghazadeh bought 7,905 shares of Scribe Therapeutics stock. The stock was acquired at an average cost of $18.25 per share, with a total value of $144,266.25. Following the completion of the transaction, the director now directly owns 3,088,888 shares of the company's stock, valued at $56,372,206. Learn More on Behzad Aghazadeh's trading history.

Who are Scribe Therapeutics' active insiders?

Scribe Therapeutics' insider roster includes Behzad Aghazadeh (Director), Carl Gordon (Director), and David Parrot (CFO). Learn More on Scribe Therapeutics' active insiders.

Are insiders buying or selling shares of Scribe Therapeutics?

During the last year, Scribe Therapeutics insiders bought shares 5 times. They purchased a total of 3,727,237 shares worth more than $56,291,746.20. The most recent insider tranaction occured on July, 28th when Director Behzad Aghazadeh bought 7,905 shares worth more than $144,266.25. Learn More about insider trades at Scribe Therapeutics.

Information on this page was last updated on 7/28/2026.

Behzad Aghazadeh Insider Trading History at Scribe Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/28/2026Buy7,905$18.25$144,266.253,088,888View SEC Filing Icon  
7/24/2026Buy2,383,333$15.15$36,107,494.953,080,983View SEC Filing Icon  
See Full Table

Behzad Aghazadeh Buying and Selling Activity at Scribe Therapeutics

This chart shows Behzad Aghazadeh's buying and selling at Scribe Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scribe Therapeutics Company Overview

Scribe Therapeutics logo
Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc. is based in ALAMEDA, Calif.
Read More

Today's Range

Now: $32.14
Low: $29.30
High: $33.36

50 Day Range

MA: N/A

2 Week Range

Now: $32.14
Low: $17.31
High: $39.60

Volume

303,929 shs

Average Volume

216,277 shs

Market Capitalization

$608.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A